Complications of systemic (IV) thrombolysis and endovascular (intra-arterial) treatment
| Trial | Symptomatic ICH | SAH |
|---|---|---|
| NINDS | 6.4% | 0% |
| PROACT I | 15.4% | na |
| PROACT II | 10.2% | na |
| IMS I | 6.3% | 0% |
| IMS II | 9.9% | na |
| Merci | 7.8% | 3.5% |
| Multi-Merci | 9.8% | 9.9% |
| Penumbra | 10% | 5% |
| SWIFT-all | 4.9% | 7.6% |
| SWIFT-Merci arm | 10.9% | 12.7% |
| SWIFT-Solitaire arm | 1.1% | 4.5% |